Search
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7, … [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries
Categories: Enzymes and Coenzymes, Amino Acids, Peptides, and ProteinsButalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitButalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation
Mixtures: Butalbital, Aspirin, and Caffeine, Butalbital, Aspirin and CaffeineCategories: Hypnotics and SedativesT-Cell/Histiocyte-Rich Large B-Cell Lymphoma
go.drugbank.com/conditions/DBCOND0082251Drugs: Polatuzumab vedotinSynonyms: Malignant lymphoma, large cell, cleaved and noncleaved, Malignant lymphoma - large cell cleaved and non-cleavedCatridecacog
go.drugbank.com/drugs/DB09310ApprovedWhen activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen.
Categories: Blood and Blood Forming OrgansEvinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966] … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Categories: Amino Acids, Peptides, and ProteinsBretylium
go.drugbank.com/drugs/DB01158ApprovedBretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular … Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.
Mixtures: Bretylium Tosylate 0.4% and Dextrose 5% Inj, Bretylium Tosylate 0.2% and Dextrose 5% InjProducts: Bretylate Inj 50mg/ml, Bretylium Tosylate Inj 50mg/mlCedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigational[A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … [A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells.
Categories: Nucleic Acids, Nucleotides, and NucleosidesOnasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.
Categories: Cellular and Gene Therapy, Amino Acids, Peptides, and ProteinsDiroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalDiroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225] … Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS.
Categories: Antineoplastic and Immunomodulating AgentsBetibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigationalBetibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β<sup>A-T87Q</sup>-globin) to hematopoietic stem cells in order to treat β-thalassemia. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia
Categories: Blood and Blood Forming Organs